Balaglitazone
Balaglitazone had been in phase III clinical trials for the treatment of type 2 diabetes. However, this research appears to have been discontinued.
The compound was originally developed by Dr. Reddy's Laboratories. In 2005, a co-developed agreement took place between Dr. Reddy's Laboratories and Rheoscience of the compound.
General Information
Update Date：2016-03-30
- Drug Name：
- Balaglitazone
- Research Code：
- Balaglitazone; DRF-2593; NNC-61-0645; NNC-61-2344
- Trade Name：
- MOA：
- Peroxisome proliferator-activated receptor (PPAR) agonist
- Indication：
- Type 2 diabetes
- Status：
- Phase Ⅲ (Discontinued)
- Company：
- Dr.Reddy's Laboratories (Originator) , Rheoscience
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-12-16
|
Molecular Weight | 395.43 | ||||||||||||
| Formula | C20H17N3O4S | |||||||||||||
| CAS No. | 199113-98-9 (Balaglitazone); | |||||||||||||
| Chemical Name | 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]- | |||||||||||||
| Balaglitazone （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2016-03-03
1. WO9741097A2.
1. WO0015638A1.